Eli Lilly Targets Europe, UK Launch of Weight-Loss Pill
Reuters reported on June 23 that Eli Lilly expects to launch its weight-loss pill in Europe and the UK in the second half of 2026 or early 2027, targeting out-of-pocket patients.
According to Reuters on June 23, Eli Lilly and Company (NYSE:LLY) expects to launch its weight-loss pill in Europe and the United Kingdom in the second half of 2026 or early 2027. The company plans to target patients paying out-of-pocket, a move that could broaden access to obesity treatments.
The Product
The new pill, whose brand name has not been disclosed, represents an oral alternative to current injections like Mounjaro and Zepbound. Eli Lilly aims to offer a more convenient option for patients, potentially improving treatment adherence.
Pricing and Availability
Eli Lilly has not yet announced specific pricing for the pill in Europe or the UK. It is expected to be available by prescription, with an initial focus on the out-of-pocket market rather than broad insurance coverage.
Competition
Eli Lilly faces competition from Novo Nordisk, which produces Wegovy (injectable) and Rybelsus pill (for type 2 diabetes). Several other companies are also developing oral weight-loss pills, making the race intense.
Potential Impact on the Company
The pill launch is expected to boost Eli Lilly's revenue in the growing obesity sector. However, success depends on regulatory approvals and the company's ability to price the product competitively.
Frequently Asked Questions
Found this useful? Share it